Literature DB >> 8020140

Inhibitory effect of silymarin, an anti-hepatotoxic flavonoid, on 12-O-tetradecanoylphorbol-13-acetate-induced epidermal ornithine decarboxylase activity and mRNA in SENCAR mice.

R Agarwal1, S K Katiyar, D W Lundgren, H Mukhtar.   

Abstract

In recent years, considerable emphasis has been placed on identifying new cancer chemopreventive agents which could be useful for human populations. Silymarin, an anti-oxidant flavonoid isolated from artichoke, has been shown to possess significant activity against hepatotoxicity and other pharmacological and physiological disorders. Since many antioxidants inhibit tumor promotion, and because ornithine decarboxylase (ODC) is a well known biochemical marker of tumor promotion, we assessed the effect of skin application of silymarin on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced epidermal ODC activity and ODC mRNA levels in SENCAR mice. Application of silymarin at doses of 0.5-18 mg (1-37 mumol)/mouse prior to that of TPA (2.5 micrograms) treatment resulted in significant inhibition of TPA-induced epidermal ODC activity in a dose- and time-dependent manner. Northern blot analysis revealed that topical application of silymarin at the dose of 2 mg/mouse resulted in almost complete inhibition of TPA-induced epidermal ODC mRNA. In other studies, silymarin also showed significant inhibition of epidermal ODC activity induced by several other tumor promoters, including free radical-generating compounds. Our data suggest that silymarin could be a useful anti-tumor promoting agent capable of ameliorating the tumor promoting effects of a wide range of tumor promoters.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8020140     DOI: 10.1093/carcin/15.6.1099

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  12 in total

1.  5- or/and 20-O-alkyl-2,3-dehydrosilybins: Synthesis and biological profiles on prostate cancer cell models.

Authors:  Bao Vue; Xiaojie Zhang; Timmy Lee; Nandini Nair; Sheng Zhang; Guanglin Chen; Qiang Zhang; Shilong Zheng; Guangdi Wang; Qiao-Hong Chen
Journal:  Bioorg Med Chem       Date:  2017-07-20       Impact factor: 3.641

2.  A survey on herbal management of hepatocellular carcinoma.

Authors:  Nabil Mohie Abdel-Hamid; Maiiada Hasan Nazmy; Ahmed Wahid Mahmoud; Michael Atef Fawzy; Marco Youssof
Journal:  World J Hepatol       Date:  2011-07-27

Review 3.  Silymarin and epithelial cancer chemoprevention: how close we are to bedside?

Authors:  Manjinder Kaur; Rajesh Agarwal
Journal:  Toxicol Appl Pharmacol       Date:  2006-11-15       Impact factor: 4.219

4.  A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories.

Authors:  B M Berkson
Journal:  Med Klin (Munich)       Date:  1999-10-15

Review 5.  Molecular mechanisms of inhibition of photocarcinogenesis by silymarin, a phytochemical from milk thistle (Silybum marianum L. Gaertn.) (Review).

Authors:  Mudit Vaid; Santosh K Katiyar
Journal:  Int J Oncol       Date:  2010-05       Impact factor: 5.650

6.  Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, inflammation and renal tumor promotion response.

Authors:  Gurpreet Kaur; Mohammad Athar; M Sarwar Alam
Journal:  Invest New Drugs       Date:  2009-07-10       Impact factor: 3.850

Review 7.  Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.

Authors:  Tomas Koltai; Larry Fliegel
Journal:  J Evid Based Integr Med       Date:  2022 Jan-Dec

Review 8.  Multitargeted therapy of cancer by silymarin.

Authors:  Kumaraguruparan Ramasamy; Rajesh Agarwal
Journal:  Cancer Lett       Date:  2008-05-09       Impact factor: 8.679

9.  Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells.

Authors:  G Ramakrishnan; L Lo Muzio; C M Elinos-Báez; S Jagan; T A Augustine; S Kamaraj; P Anandakumar; T Devaki
Journal:  Cell Prolif       Date:  2009-04       Impact factor: 6.831

10.  In vitro release and in vitro-in vivo correlation for silybin meglumine incorporated into hollow-type mesoporous silica nanoparticles.

Authors:  Xia Cao; Wen-Wen Deng; Min Fu; Liang Wang; Shan-Shan Tong; Ya-Wei Wei; Ying Xu; Wei-Yan Su; Xi-Ming Xu; Jiang-Nan Yu
Journal:  Int J Nanomedicine       Date:  2012-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.